Association between FDA black box warnings and Medicare formulary coverage changes

Sanket S. Dhruva, Pinar Karaca-Mandic, Nilay D Shah, Daniel L. Shaw, Joseph S. Ross

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

RESULTS: Nine drugs with at least 1 FDA-approved safer drug alternative received 10 new black box warnings for death and/or cardiovascular risk between 2007 and 2013. In response to FDA black box warnings, overall formulary restrictiveness increased for 40% (n = 4) of drugs at 1 year, and for 50% (n = 5) at 2 years. However, for the majority of drugs (n = 7), most formularies remained unrestrictive 2 years after a new black box warning.

METHODS: We identified all FDA-approved medications available in tablet or capsule formulation that received a black box warning between 2007 and 2013 related to death and/or cardiovascular risk. We then determined formulary coverage of these drugs pre-black box warning, 1 year after, and 2 years after. For each formulary, we identified formulary restrictiveness, defined as: unrestrictive coverage (no prior authorization or step therapy), restrictive coverage (prior authorization or step therapy required), or no coverage.

CONCLUSIONS: Medicare formularies became more restrictive for half of the drugs that recently received new FDA black box warnings for death and/or cardiovascular risk and for which safer drug alternatives are available. However, a substantial proportion of formularies remained unrestrictive, suggesting inconsistent responses to new safety information to curtail the use of these medications.

OBJECTIVES: To assess whether Medicare formularies restrict access to drugs receiving new FDA black box warnings for which safer drug alternatives are available.

STUDY DESIGN: A retrospective analysis using Medicare Prescription Drug Plan Formulary files to determine formulary changes for drugs receiving FDA black box warnings between 2007 and 2013.

Original languageEnglish (US)
Pages (from-to)e310-e315
JournalThe American journal of managed care
Volume23
Issue number9
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Association between FDA black box warnings and Medicare formulary coverage changes'. Together they form a unique fingerprint.

  • Cite this

    Dhruva, S. S., Karaca-Mandic, P., Shah, N. D., Shaw, D. L., & Ross, J. S. (2017). Association between FDA black box warnings and Medicare formulary coverage changes. The American journal of managed care, 23(9), e310-e315.